Physician profile
John V Pinski
NPI 1316911779
$1,448.73
in general payments reported to CMS, 2019-2025
14 companies · $17.41 in 2025
The $17.41 reported for 2025 was less than what a typical Urology provider received nationally (typical 2025 total: $631).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $305 · 2020: $242 · 2021: $391 · 2022: $293 · 2023: $16.00 · 2024: $185 · 2025: $17.41.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $218.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $218.44 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astellas Pharma US INC | $390.69 | 2019-2022 | |
| Pfizer INC. | $224.88 | 2019-2024 | |
| Boston Scientific Corporation | $174.40 | 2021-2022 | |
| Urovant Sciences INC | $155.01 | 2021-2022 | |
| Abbvie INC. | $149.99 | 2019-2024 | |
| Allergan, INC. | $134.85 | 2019-2021 | |
| Tolmar Pharmaceuticals, INC. | $48.57 | 2021 | |
| Janssen Biotech, INC. | $39.06 | 2019 | |
| Coloplast Corp | $30.62 | 2019 | |
| 180 Medical, INC. | $30.28 | 2022-2025 | Gentlecath Glide |
| Ferring Pharmaceuticals INC. | $19.49 | 2019 | |
| Endo USA, INC. | $18.70 | 2024 | Xiaflex |
| Sumitomo Pharma America, INC. | $16.10 | 2024 | Gemtesa |
| Myovant Sciences INC. | $16.09 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw John Pinski listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.